Pretreatment Serum Amyloid A and C-reactive Protein Comparing with Epstein-Barr Virus DNA as Prognostic Indicators in Patients with Nasopharyngeal Carcinoma: A Prospective Study
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose The measuring Epstein-Barr virus (EBV) DNA is an important predictor of nasopharyngeal carcinoma (NPC). This study evaluated the predictive value of pretreatment serum amyloid A (SAA) and C-reactive protein (CRP) comparing with EBV DNA in patients with NPC. Materials and Methods In an observational study of 419 non-metastatic NPC patients, we prospectively evaluated the prognostic effects of pretreatment SAA, CRP, and EBV DNA on survival. The primary endpoint was progress-free survival (PFS). Results The median level of SAA and CRP was 4.28 mg/L and 1.88 mg/L, respectively. For the high- SAA group (> 4.28 mg/L) versus the low-SAA ( 4.28 mg/L) group and the high-CRP group (> 1.88 mg/L) versus the low-CRP ( 1.88 mg/L) group, the 5-year PFS was 64.5% versus 73.1% (p=0.013) and 65.2% versus 73.3% (p=0.064), respectively. EBV DNA detection showed a superior predictive result, the 5-year PFS in the EBV DNA 1,500 copies/mL group was obviously different than the EBV DNA < 1,500 copies/mL group (62.2% versus 77.8%, p < 0.001). Multifactorial Cox regression analysis confirmed that in the PFS, the independent prognostic factors were including EBV DNA (hazard ratio [HR], 1.788; p=0.009), tumour stage (HR, 1.903; p=0.021), and node stage (HR, 1.498; p=0.049), but the SAA and CRP were not included in the independent prognostic factors. Conclusion The results of SAA and CRP had a certain relationship with the prognosis of NPC, and the prognosis of patients with high level of SAA and CRP were poor. However, the predictive ability of SAA and CRP was lower than that of EBV DNA.
Abstract
Purpose The measuring Epstein-Barr virus (EBV) DNA is an important predictor of nasopharyngeal carcinoma (NPC). This study evaluated the predictive value of pretreatment serum amyloid A (SAA) and C-reactive protein (CRP) comparing with EBV DNA in patients with NPC. Materials and Methods In an observational study of 419 non-metastatic NPC patients, we prospectively evaluated the prognostic effects of pretreatment SAA, CRP, and EBV DNA on survival. The primary endpoint was progress-free survival (PFS). Results The median level of SAA and CRP was 4.28 mg/L and 1.88 mg/L, respectively. For the high- SAA group (> 4.28 mg/L) versus the low-SAA ( 4.28 mg/L) group and the high-CRP group (> 1.88 mg/L) versus the low-CRP ( 1.88 mg/L) group, the 5-year PFS was 64.5% versus 73.1% (p=0.013) and 65.2% versus 73.3% (p=0.064), respectively. EBV DNA detection showed a superior predictive result, the 5-year PFS in the EBV DNA 1,500 copies/mL group was obviously different than the EBV DNA < 1,500 copies/mL group (62.2% versus 77.8%, p < 0.001). Multifactorial Cox regression analysis confirmed that in the PFS, the independent prognostic factors were including EBV DNA (hazard ratio [HR], 1.788; p=0.009), tumour stage (HR, 1.903; p=0.021), and node stage (HR, 1.498; p=0.049), but the SAA and CRP were not included in the independent prognostic factors. Conclusion The results of SAA and CRP had a certain relationship with the prognosis of NPC, and the prognosis of patients with high level of SAA and CRP were poor. However, the predictive ability of SAA and CRP was lower than that of EBV DNA.
참고문헌 (28)
- Wee JT, "Is nasopharyngeal cancer really a "Cantonese cancer"?", Chin J Cancer, 29, pp.517~526 (2010)[DOI]
- Blanchard P, "Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis", Lancet Oncol, 16, pp.645~655 (2015)[DOI]
- Wei WI, "Nasopharyngeal carcinoma", Lancet, 365, pp.2041~2054 (2005)[DOI]
- Ludwig JA, "Biomarkers in cancer staging, prognosis and treatment selection", Nat Rev Cancer, 5, pp.845~856 (2005)[DOI]
- Lin JC, "Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma", N Engl J Med, 350, pp.2461~2470 (2004)[DOI]
- Coussens LM, "Inflammation and cancer", Nature, 420, pp.860~867 (2002)[DOI]
- Schultz DR, "Properties of four acute phase proteins: C-reactive protein, serum amyloid A protein, alpha 1-acid glycoprotein, and fibrinogen", Semin Arthritis Rheum, 20, pp.129~147 (1990)[DOI]
- Chan DC, "Evaluation of serum amyloid A as a biomarker for gastric cancer", Ann Surg Oncol, 14, pp.84~93 (2007)
- Cho WC, "Identification of serum amyloid a protein as a potentially useful biomarker to monitor relapse of nasopharyngeal cancer by serum proteomic profiling", Clin Cancer Res, 10(1), pp.43~52 (2004)[DOI]
- Howard BA, "Identification and validation of a potential lung cancer serum biomarker detected by matrix-assisted laser desorption", ionization-time of flight spectra analysis, 2003, pp.3, 1720~1724
- Liao Q, "Serum proteome analysis for profiling protein markers associated with carcinogenesis and lymph node metastasis in nasopharyngeal carcinoma", Clin Exp Metastasis, 25, pp.465~476 (2008)[DOI]
- Pierce BL, "Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients", J Clin Oncol, 27, pp.3437~3444 (2009)[DOI]
- Tang LQ, "Highsensitivity C-reactive protein complements plasma Epstein- Barr virus deoxyribonucleic acid prognostication in nasopharyngeal carcinoma: a large-scale retrospective and prospective cohort study", Int J Radiat Oncol Biol Phys, 91, pp.325~336 (2015)[DOI]
- Xia WX, "The impact of baseline serum C-reactive protein and C-reactive protein kinetics on the prognosis of metastatic nasopharyngeal carcinoma patients treated with palliative chemotherapy", PLoS One, 8, pp.e76958~ (2013)[DOI]
- An X, "Plasma Epstein-Barr virus DNA level strongly predicts survival in metastatic", recurrent nasopharyngeal carcinoma treated with palliative chemotherapy, 2011, pp.117, 3750~3757
- Yamada T, "Serum amyloid A (SAA): a concise review of biology, assay methods and clinical usefulness", Clin Chem Lab Med, 37, pp.381~388 (1999)
- Malle E, "Human serum amyloid A (SAA) protein: a prominent acute-phase reactant for clinical practice", Eur J Clin Invest, 26, pp.427~435 (1996)[DOI]
- Biran H, "Serum amyloid A (SAA) variations in patients with cancer: correlation with disease activity, stage, primary site, and prognosis", J Clin Pathol, 39, pp.794~797 (1986)[DOI]
- Liu DH, "Serum amyloid A protein: a potential biomarker correlated with clinical stage of lung cancer", Biomed Environ Sci, 20, pp.33~40 (2007)
- Wood SL, "Association of serum amyloid A protein and peptide fragments with prognosis in renal cancer", Br J Cancer, 103, pp.101~111 (2010)[DOI]
- Vermaat JS, "Validation of serum amyloid alpha as an independent biomarker for progression-free and overall survival in metastatic renal cell cancer patients", Eur Urol, 62, pp.685~695 (2012)[DOI]
- Cho WC, "Serum amyloid A is elevated in the serum of lung cancer patients with poor prognosis", Br J Cancer, 102, pp.1731~1735 (2010)[DOI]
- Sung HJ, "Identification and validation of SAA as a potential lung cancer biomarker and its involvement in metastatic pathogenesis of lung cancer", J Proteome Res, 10, pp.1383~1395 (2011)[DOI]
- Toriola AT, "Biomarkers of inflammation are associated with colorectal cancer risk in women but are not suitable as early detection markers", Int J Cancer, 132, pp.2648~2658 (2013)[DOI]
- Cocco E, "Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer", Br J Cancer, 101, pp.335~341 (2009)[DOI]
- Leung SF, "Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma", J Clin Oncol, 24, pp.5414~5418 (2006)[DOI]
- Findeisen P, "Serum amyloid A as a prognostic marker in melanoma identified by proteomic profiling", J Clin Oncol, 27, pp.2199~2208 (2009)[DOI]
- Pierce BL, "Correlates of circulating C-reactive protein and serum amyloid A concentrations in breast cancer survivors", Breast Cancer Res Treat, 114, pp.155~167 (2009)[DOI]